Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Tal Akriv"'
Autor:
Alessio D. Nahmad, Yuval Raviv, Miriam Horovitz-Fried, Ilan Sofer, Tal Akriv, Daniel Nataf, Iris Dotan, Yaron Carmi, David Burstein, Yariv Wine, Itai Benhar, Adi Barzel
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-10 (2020)
Chronic antiretroviral therapy does not eradicate HIV infection. Here, the authors describe a potentially one-shot alternative by engineering B cells to express anti-HIV antibodies and undergo memory retention, isotype switching and clonal expansion
Externí odkaz:
https://doaj.org/article/53cea78635c1437b9150abc735992dd8
Autor:
Miriam Horovitz-Fried, Tal Akriv, Yariv Wine, Nahmad Ad, David Burstein, Daniel Nataf, Ilan Sofer, Itai Benhar, Adi Barzel, Yuval Raviv, Yaron Carmi, Iris Dotan
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-10 (2020)
Nature Communications
Nature Communications
HIV viremia can be controlled by chronic antiretroviral therapy. As a potentially single-shot alternative, B cells engineered by CRISPR/Cas9 to express anti-HIV broadly neutralizing antibodies (bNAbs) are capable of secreting high antibody titers. He
Autor:
Yariv Wine, Horovitz-Fried M, Itai Benhar, Sofer I, David Burstein, Nahmad Ad, Yuval Raviv, Iris Dotan, Daniel Nataf, Adi Barzel, Tal Akriv
HIV viremia can be controlled by chronic antiretroviral therapy. As a potentially single-shot alternative, B cells engineered by CRISPR/Cas9 to express anti-HIV broadly neutralizing antibodies (bNAbs) were shown capable of secreting high antibody tit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97f3d1ea20ff80f44338d7b69f0e1d21